Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis

University of Jordan10 enrolled

Overview

Induction of autologous angiogenesis in patients with critical limb ischemia using platelet lysate.

Ten male and female patients diagnosed with Peripheral artery disease (PAD), will be recruited. This diagnosis will be based on medical history, physical examinations, laboratory tests, and specific diagnostic tests. Patients qualified for this study, are patients with distal extremity ischemia indicated by claudication and rest pain present for a minimum of 4 weeks without evidence of improvement in response to conventional drug therapy; showed angiographic evidence of PAD in the affected limb; and were not candidates for surgical revascularization. Platelet lysate will be injected intramuscularly at different sites of the gastrocnemius muscle. The purpose of this study is to evaluate the safety and efficacy of platelet lysate injections into ischematic limbs of patients with PAD.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Critical Limb Ischemia

Interventions

Platelet lysateBIOLOGICAL

Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Competent and willing to give informed consent, and to be available for all baseline treatment and follow up examinations required by the protocol. * Gender: Male or female. * Established Peripheral arterial disease, clinically and hemodynamically confirmed as per Rutherford 3, 4 and * History of intermittent claudication for \> eight weeks. * Limited exercise due to moderate to severe claudication. * Resting ankle brachial index (ABI) \< 0.85, toe pressure ≤ 60 mm Hg, Toe brachial index (TBI) \<0.6, or Trans-cutaneous oxygen pressure (TcPO2) ≤ 60 mmHg in the foot. * Not eligible for surgical or radiological revascularization. * In case of diabetic patients, he/she should be on medication and fairly controlled (HbA1c \<10%). * Normal liver enzymes, serum creatinine \< 1.4 * Normal platelet count. * On regular medication for hypertension if any. * No evidence of malignancy * Low Questionnaire scores. * Body mass index \<30. Exclusion Criteria: * Women with child bearing potential, pregnant and lactating women. * Rheumatoid Arthritis. * History of neoplasm or malignancy in the past 10 years. * Reported unstable cardiovascular disease, heart failure or symptomatic postural hypotension within 6 months before screening. * Leg edema * Inflammatory or progressive fibrotic disorder * Renal insufficiency or failure * History of infectious disorder. * Chronic inflammatory disease * History of stroke or myocardial infarction ( \< 3 months). * Bleeding or clotting disorder, use of oral anticoagulant therapy (heparin, warfarin). * Lab values for * Hemoglobin \<10 g/dl. * Platelet count \<100,000. * Prothrombin time/ partial thromboplastin time (PT/PTT)\> 3 seconds. * Alanine aminotrasferase (ALT) and aspartatet aminotrasferase (AST) \> 1.5x of the normal lab value. * Creatinine ≥ 1.4 * Poorly controlled diabetes (HbA1c ≥10) * Bilirubin \> 1.5x of the normal lab value. * Systemic autoimmune disease. * Receiving immunosuppressant medications. * Uncontrolled hypertension or hypotension. * Abdominal aortic aneurism \> 5 cm. * Active or untreated Tuberculosis.

Outcomes

Primary Outcomes

Assessment the safety of platelet lysate injection

Patients will be assessed for any relevant adverse event resulting from the platelet lysate injection

Time frame: 6 months

Secondary Outcomes

Assessment the efficacy of platelet lysate injection

Assessing the therapeutic benefit of all four platelet lysate injections by ankle brachial index (ABI).

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.